Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer

✍ Scribed by C. Emmanouilides; M. Pegram; R. Robinson; R. Hecht; F. Kabbinavar; W. Isacoff

• Publisher: Springer
• Year: 2004
• Tongue: English
• Weight: 63 KB
• Volume: 8
• Category: Article
• ISSN: 1123-6337
• DOI: 10.1007/s10151-004-0110-4